The effect of biologic therapy for immune-mediated inflammatory diseases on clinical outcomes of COVID-19 in the greater Houston area: A retrospective chart review

Affiliations

¹ University of Texas at Houston McGovern Medical School, Houston, Texas.
² Department of Dermatology, University of Texas Health Science Center at Houston, Houston, Texas.
³ Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team, University of Texas, MD Anderson Cancer Center, Houston, Texas.
⁴ Department of Dermatology, MD Anderson Cancer Center, Houston, Texas. Electronic address: opacha@mdanderson.org.

Kevin P Lee et al. J Am Acad Dermatol. 2022 Sep.

. 2022 Sep;87(3):658-660.

doi: 10.1016/j.jaad.2021.12.054. Epub 2022 Jan 10.

¹ University of Texas at Houston McGovern Medical School, Houston, Texas.
² Department of Dermatology, University of Texas Health Science Center at Houston, Houston, Texas.
³ Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team, University of Texas, MD Anderson Cancer Center, Houston, Texas.
⁴ Department of Dermatology, MD Anderson Cancer Center, Houston, Texas. Electronic address: opacha@mdanderson.org.

No abstract available

Conflict of interest statement

Conflicts of interest None disclosed.

1. Guidance on the use of immunosuppressive agents. American Academy of Dermatology. https://www.aad.org/member/practice/coronavirus/clinical-guidance/biologics
1. American community survey data. United States Census Bureau. https://www.census.gov/programs-surveys/acs/data.html
1. Coronavirus (COVID-19) updates. Texas Medical Center. https://www.tmc.edu/coronavirus-updates/
1. Avouac J., Drumez E., Hachulla E., et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021;3(6):e419–e426. - PMC - PubMed
1. Mahil S.K., Dand N., Mason K.J., et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2021;147(1):60–71. - PMC - PubMed